BioGenCell in partnership with Laniado raises $16 million for microvascular disease treatment
Israeli biotechnology company BioGenCell has completed a $16 million Seed round led by private investor Marius Nacht. Founder, Dr. Yael Porat and Prof. Michael Belkin, developed technology using stem cells from patients’ own blood to treat microvascular diseases.
BioGenCell is located at and has a strategic partnership with Laniado Hospital in Netanya. The product, intended for the treatment of chronic limb-threatening ischemia (CLI), typically found in patients with diabetes and heavy smokers is a painful disease caused by severe blockage of blood flow in the small blood vessels, leading to pain, chronic inflammation, sores and loss of limbs. Data shows that within one year of diagnosis, 30% of patients with the disease are candidates for amputation, with a 20% morbidity rate.
A unit of blood is collected from the patient, which can be done at any clinic, with no need for anesthesia. The rapid production process of the patented drug takes approximately 24 hours, is biologically efficient, and employs a proprietary unified algorithm to create personalised medicine.
Processed stem cells taken from the patient are injected into the leg muscle which promote the production of new blood vessels bypassing damaged blood vessels which renews delivery of blood to the leg. The immune helper cells reduce local inflammation, cleaning the damage and function according to tissue needs.
Treatment is performed once with 30 injections, in any standard treatment room and according to the results from first patients, even after numerous years with the disease, the injected cells have a long-lasting therapeutic effect. Improvement is seen after 1 month and continues over years.
The future product line of the medical stem cells, includes products that may be usable to restore tissues damaged by diabetes, kidney failure, pulmonary hypertension, heart failure, stroke, blindness, and more.
In Phase I of clinical trials, 5 incurable patients who had previously tried all available treatments and were about to undergo limb amputation were successfully treated. Cell therapy was found safe with all patients improved in the parameters of: improved blood flow, healing of chronic sores, ability to walk, an improved quality of life and prevention of amputation.
BioGenCell recently received FDA approval permission to continue to Phase II trials, designed as a controlled double-blind trial in otherwise incurable patients.